At present, there is no reliable biomarker for the diagnosis of pancreatic ductal adenocarcinoma (PDAC). Due to this, together with the asymptomatic nature of the cancer, PDAC is often diagnosed at an
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate of 10-15% due to late-stage diagnosis and limited efficacy of existing treatments. T
